CL2016001976A1 - Composición que comprende inmunoglobulina m (igm) derivada de plasma y su uso para el tratamiento de enfermedades infecciosas relacionadas con exotoxinas citotóxicas - Google Patents

Composición que comprende inmunoglobulina m (igm) derivada de plasma y su uso para el tratamiento de enfermedades infecciosas relacionadas con exotoxinas citotóxicas

Info

Publication number
CL2016001976A1
CL2016001976A1 CL2016001976A CL2016001976A CL2016001976A1 CL 2016001976 A1 CL2016001976 A1 CL 2016001976A1 CL 2016001976 A CL2016001976 A CL 2016001976A CL 2016001976 A CL2016001976 A CL 2016001976A CL 2016001976 A1 CL2016001976 A1 CL 2016001976A1
Authority
CL
Chile
Prior art keywords
igm
plasma
derived
treatment
immunoglobulin
Prior art date
Application number
CL2016001976A
Other languages
English (en)
Inventor
David A Ross
Thomas Barnett
Original Assignee
Grifols Worldwide Operations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Worldwide Operations Ltd filed Critical Grifols Worldwide Operations Ltd
Publication of CL2016001976A1 publication Critical patent/CL2016001976A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1741—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals alpha-Glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

COMPOSICIÓN QUE COMPRENDE INMUNOGLOBULINA M (IgM) DERIVADA DE PLASMA Y SU USO PARA EL TRATAMIENTO DE ENFERMEDADES INFECCIOSAS RELACIONADAS CON EXOTOXINAS CITOTÓXICAS
CL2016001976A 2015-08-06 2016-08-05 Composición que comprende inmunoglobulina m (igm) derivada de plasma y su uso para el tratamiento de enfermedades infecciosas relacionadas con exotoxinas citotóxicas CL2016001976A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562201910P 2015-08-06 2015-08-06

Publications (1)

Publication Number Publication Date
CL2016001976A1 true CL2016001976A1 (es) 2017-03-17

Family

ID=56507435

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001976A CL2016001976A1 (es) 2015-08-06 2016-08-05 Composición que comprende inmunoglobulina m (igm) derivada de plasma y su uso para el tratamiento de enfermedades infecciosas relacionadas con exotoxinas citotóxicas

Country Status (16)

Country Link
US (2) US10570194B2 (es)
EP (1) EP3135688A3 (es)
JP (1) JP6711719B2 (es)
KR (1) KR20170017802A (es)
CN (1) CN106421779A (es)
AR (1) AR105595A1 (es)
AU (1) AU2016208312B2 (es)
BR (1) BR102016017684A2 (es)
CA (1) CA2937193C (es)
CL (1) CL2016001976A1 (es)
IL (1) IL247010B (es)
MX (1) MX2016009887A (es)
RU (1) RU2731108C2 (es)
SG (2) SG10201606213SA (es)
TW (1) TWI720999B (es)
UY (1) UY36815A (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10570194B2 (en) * 2015-08-06 2020-02-25 Grifols Worldwide Operations Limited Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin M (IgM)
WO2020109621A1 (en) * 2018-11-30 2020-06-04 Csl Behring Ag Methods and compositions for preventing or treating acute exacerbations with polyclonal immunoglobulin
AU2021284903A1 (en) * 2020-06-03 2023-02-02 Grifols Worldwide Operations Limited Hyperimmune IgG and/or IgM compositions and method for preparing thereof and method for obtaining hyperimmune human plasma from a donor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2691708B2 (ja) 1984-09-26 1997-12-17 住友製薬株式会社 ヒトモノクローナル抗体およびその製法
GB8426464D0 (en) * 1984-10-19 1984-11-28 Technology Licence Co Ltd Monoclonal antibodies
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
DE3875852T2 (de) * 1987-08-10 1993-03-18 Miles Inc Gereinigtes igm.
IL90281A (en) * 1988-06-06 1994-10-07 Miles Inc Preparations containing MGI antibodies
DE3927111C3 (de) 1989-08-17 1994-09-01 Biotest Pharma Gmbh Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate
US5240909B1 (en) * 1990-03-14 1998-01-20 Dietrich Nitsche Use of lactoferrin for treatment of toxic effects of endotoxins
US7473423B2 (en) * 1994-04-29 2009-01-06 Mayo Foundation For Medical Education And Research Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
EP1779849A1 (en) 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of septic shock
US8021645B2 (en) * 2006-12-13 2011-09-20 Simon Michael R Synthesis of human secretory IgA and IgM and the formation of a medicament therefrom
US7794721B2 (en) 2006-12-13 2010-09-14 Simon Michael R Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith
GB0717864D0 (en) 2007-09-13 2007-10-24 Peptcell Ltd Peptide sequences and compositions
JP2011519974A (ja) * 2008-05-12 2011-07-14 ストロックス バイオファーマスーティカルズ，エルエルシー 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）に特異的な抗体製剤
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
EP3995158A1 (en) 2012-11-06 2022-05-11 Imbed Biosciences, Inc. Methods and compositions for wound healing
US10570194B2 (en) * 2015-08-06 2020-02-25 Grifols Worldwide Operations Limited Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin M (IgM)
US9913903B2 (en) * 2015-08-06 2018-03-13 Grifols Worldwide Operations Limited Method for the treatment or prevention of infection-related immune conditions using a composition comprising IgM

Also Published As

Publication number Publication date
US11208471B2 (en) 2021-12-28
BR102016017684A2 (pt) 2017-02-14
TW201705985A (zh) 2017-02-16
CN106421779A (zh) 2017-02-22
CA2937193A1 (en) 2017-02-06
KR20170017802A (ko) 2017-02-15
JP2017036264A (ja) 2017-02-16
EP3135688A3 (en) 2017-05-17
SG10202001042PA (en) 2020-03-30
RU2731108C2 (ru) 2020-08-28
US20200223908A1 (en) 2020-07-16
TWI720999B (zh) 2021-03-11
AU2016208312B2 (en) 2022-04-14
AR105595A1 (es) 2017-10-18
SG10201606213SA (en) 2017-03-30
US20170037115A1 (en) 2017-02-09
JP6711719B2 (ja) 2020-06-17
UY36815A (es) 2016-09-30
IL247010B (en) 2021-05-31
RU2016131195A3 (es) 2019-12-19
US10570194B2 (en) 2020-02-25
AU2016208312A1 (en) 2017-02-23
EP3135688A2 (en) 2017-03-01
IL247010A0 (en) 2016-12-29
MX2016009887A (es) 2017-02-06
CA2937193C (en) 2024-01-30
RU2016131195A (ru) 2018-02-01

Similar Documents

Publication Publication Date Title
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2017001798A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas.
GT201600215A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
CL2016002877A1 (es) Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos.
CL2016001579A1 (es) Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, así como su uso para la preparación de medicamentos.
CL2015002855A1 (es) Derivados de oxopiridina sustituida.
CL2016003056A1 (es) Dinucleótidos ciclicos moduladores de sting; composición y combinación farmacéutica que los comprende y uso de los mismos para el tratamiento de enfermedades tales como inflamación, enfermedades alérgicas y autoinmunes, enfermedades infecciosas y cancer.
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016000493A1 (es) Inhibidores de polimerasa hcv.
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
CL2016002509A1 (es) Composiciones para modular la expresión de sod-1
UY36311A (es) Indazoles sustituidos con bencilo
CL2014001956A1 (es) Compuestos derivados de beta-lactamicos sustituidos con amidina; metodo para su preparacion; medicamento que los comprende; y su uso para el tratamiento y/o profilaxis de infecciones bacterianas.
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
BR112017012679A2 (pt) compostos imunomoduladores, seus usos, composição e kit
EA201691582A1 (ru) Новые фармацевтические препараты
BR112017012859A2 (pt) fosforamidatos para o tratamento do vírus da hepatite b
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
DK3785733T3 (da) Farmaceutisk sammensætning til behandling af autisme
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
CL2017002170A1 (es) Desacetoxitubulisina h y análogos de esta.
CR20170005A (es) Derivados de insoindolina
CL2017000152A1 (es) Derivados de isoindolinona